Citadel Advisors’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54.1K | Buy |
26,800
+6,200
| +30% | +$13.9K | ﹤0.01% | 12374 |
|
|
2025
Q4 | $33.6K | Buy |
+20,600
| New | +$29.8K | ﹤0.01% | 12191 |
|
|
2025
Q3 | – | Sell |
-15,200
| Closed | -$17.6K | – | 14156 |
|
|
2025
Q2 | $17.6K | Buy |
15,200
+400
| +3% | +$485 | ﹤0.01% | 12131 |
|
|
2025
Q1 | $13.7K | Buy |
14,800
+8,200
| +124% | +$8.17K | ﹤0.01% | 13393 |
|
|
2024
Q4 | $5.68K | Buy |
6,600
+2,100
| +47% | +$2.96K | ﹤0.01% | 13844 |
|
|
2024
Q3 | $7.47K | Sell |
4,500
-4,700
| -51% | -$8.18K | ﹤0.01% | 13363 |
|
|
2024
Q2 | $14.8K | Buy |
9,200
+5,100
| +124% | +$10.3K | ﹤0.01% | 12857 |
|
|
2024
Q1 | $9.39K | Sell |
4,100
-4,296
| -51% | -$9.95K | ﹤0.01% | 13505 |
|
|
2023
Q4 | $18.9K | Sell |
8,396
-3,700
| -31% | -$8.93K | ﹤0.01% | 12665 |
|
|
2023
Q3 | $36.5K | Buy |
12,096
+3,200
| +36% | +$12.1K | ﹤0.01% | 12105 |
|
|
2023
Q2 | $36.7K | Sell |
8,896
-18,400
| -67% | -$72.2K | ﹤0.01% | 12145 |
|
|
2023
Q1 | $102K | Sell |
27,296
-7,364
| -21% | -$35.3K | ﹤0.01% | 11230 |
|
|
2022
Q4 | $194K | Buy |
34,660
+3,798
| +12% | +$22.4K | ﹤0.01% | 10193 |
|
|
2022
Q3 | $205K | Buy |
+30,862
| New | +$250K | ﹤0.01% | 10358 |
|
|
2022
Q2 | – | Sell |
-3,166
| Closed | -$60K | – | 14134 |
|
|
2022
Q1 | $60K | Sell |
3,166
-3,576
| -53% | -$56.2K | ﹤0.01% | 12684 |
|
|
2021
Q4 | $120K | Buy |
6,742
+1,820
| +37% | +$54.5K | ﹤0.01% | 12529 |
|
|
2021
Q3 | $182K | Buy |
4,922
+280
| +6% | +$12.4K | ﹤0.01% | 12116 |
|
|
2021
Q2 | $276K | Sell |
4,642
-1,096
| -19% | -$66.4K | ﹤0.01% | 11465 |
|
|
2021
Q1 | $384K | Buy |
5,738
+2,960
| +107% | +$232K | ﹤0.01% | 10282 |
|
|
2020
Q4 | $168K | Sell |
2,778
-10
| -0.4% | -$683 | ﹤0.01% | 9868 |
|
|
2020
Q3 | $220K | Buy |
2,788
+1,728
| +163% | +$138K | ﹤0.01% | 8655 |
|
|
2020
Q2 | $66K | Buy |
1,060
+816
| +334% | +$47.5K | ﹤0.01% | 9189 |
|
|
2020
Q1 | $13K | Sell |
244
-168
| -41% | -$16.7K | ﹤0.01% | 9388 |
|
|
2019
Q4 | $50K | Sell |
412
-226
| -35% | -$32.5K | ﹤0.01% | 8754 |
|
|
2019
Q3 | $116K | Sell |
638
-216
| -25% | -$30.4K | ﹤0.01% | 8418 |
|
|
2019
Q2 | $111K | Sell |
854
-662
| -44% | -$119K | ﹤0.01% | 8503 |
|
|
2019
Q1 | $369K | Buy |
1,516
+90
| +6% | +$23.8K | ﹤0.01% | 7298 |
|
|
2018
Q4 | $272K | Sell |
1,426
-570
| -29% | -$139K | ﹤0.01% | 7429 |
|
|
2018
Q3 | $655K | Sell |
1,996
-174
| -8% | -$53.3K | ﹤0.01% | 6266 |
|
|
2018
Q2 | $677K | Buy |
2,170
+1,204
| +125% | +$368K | ﹤0.01% | 5879 |
|
|
2018
Q1 | $235K | Sell |
966
-894
| -48% | -$251K | ﹤0.01% | 7098 |
|
|
2017
Q4 | $562K | Buy |
1,860
+1,342
| +259% | +$374K | ﹤0.01% | 5472 |
|
|
2017
Q3 | $137K | Sell |
518
-226
| -30% | -$65.3K | ﹤0.01% | 6918 |
|
|
2017
Q2 | $196K | Sell |
744
-282
| -27% | -$70.6K | ﹤0.01% | 6587 |
|
|
2017
Q1 | $369K | Sell |
1,026
-372
| -27% | -$115K | ﹤0.01% | 5550 |
|
|
2016
Q4 | $403K | Buy |
1,398
+938
| +204% | +$291K | ﹤0.01% | 5240 |
|
|
2016
Q3 | $157K | Sell |
460
-550
| -54% | -$201K | ﹤0.01% | 6442 |
|
|
2016
Q2 | $429K | Buy |
1,010
+462
| +84% | +$190K | ﹤0.01% | 4705 |
|
|
2016
Q1 | $175K | Buy |
548
+232
| +73% | +$79.1K | ﹤0.01% | 5737 |
|
|
2015
Q4 | $164K | Sell |
316
-302
| -49% | -$111K | ﹤0.01% | 6074 |
|
|
2015
Q3 | $181K | Sell |
618
-102
| -14% | -$36.3K | ﹤0.01% | 6275 |
|
|
2015
Q2 | $283K | Buy |
720
+126
| +21% | +$44.5K | ﹤0.01% | 5828 |
|
|
2015
Q1 | $180K | Buy |
594
+220
| +59% | +$53.7K | ﹤0.01% | 6304 |
|
|
2014
Q4 | $83K | Buy |
374
+50
| +15% | +$10.3K | ﹤0.01% | 6801 |
|
|
2014
Q3 | $75K | Buy |
324
+120
| +59% | +$30.2K | ﹤0.01% | 6633 |
|
|
2014
Q2 | $45K | Buy |
204
+74
| +57% | +$16.5K | ﹤0.01% | 6823 |
|
|
2014
Q1 | $41K | Buy |
+130
| New | +$41.4K | ﹤0.01% | 6902 |
|
Other funds holding TXMD
RCMNY
CC
SCM
VCM
TC
ACM
Citadel Advisors's TXMD Position: Q1 2026 in Review
Citadel Advisors increased its TherapeuticsMD (TXMD) stake by 142% in Q1 2026, buying an estimated $90.1K and bringing the position to 68,314 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #11751.
Citadel Advisors first reported a position in TXMD in Q1 2014 and has held it in 39 quarters since. The position peaked at $18.6M in Q1 2017. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.
- Citadel Advisors held 68,314 shares of TherapeuticsMD worth $138K as of Q1 2026.
- Citadel Advisors bought 40,074 TherapeuticsMD shares in Q1 2026, an estimated $90.1K.
- TherapeuticsMD made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11751 holding.
- Citadel Advisors first reported a position in TherapeuticsMD in Q1 2014 and has held it in 39 quarters since.
- Citadel Advisors's TherapeuticsMD position peaked at $18.6M in Q1 2017.
- 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.